Latest news with #HPV-related
The Hindu
3 days ago
- Health
- The Hindu
‘Conquer HPV' conclave begins
The 'Conquer HPV (Human papillomavirus) & Cancer Conclave 2025' was launched here on Saturday (May 31) as part of a nationwide public health initiative led by the Serum Institute of India (SII). India continues to face a significant burden of HPV-related diseases, particularly cervical cancer, which remains the second most common cancer among women in the country, said a release issued here. According to the ICO/IARC Information Centre on HPV and Cancer (2023), India reports over 1.23 lakh new cervical cancer cases and over 77,000 related deaths annually. Apart from this, up to 90% of anal cancers & 63% of penile cancers are associated with HPV, it said. Speakers at a discussion held here on the public health implications of HPV said that early awareness and timely prevention were essential, with peak HPV infection occurring between the ages of 15 to 25, according to the release.
Hindustan Times
4 days ago
- Health
- Hindustan Times
Men should also take HPV vaccine: Experts
Health experts said that males can spread human papillomavirus (HPV) to their female partners and are also at risk. While HPV is often associated with cervical cancer in women, it also causes several serious diseases in men, including penile cancer, anal cancer, and oropharyngeal cancer as well as genital warts. Panel of medical specialists took part in discussion on public health implications of HPV at the 'Conquer HPV & Cancer Conclave 2025' organised by the Serum Institute of India (SII). They advised routine screening tests to detect HPV-related disease early in girls. With peak HPV infection occurring between ages 15 to 25, early awareness and timely preventive action are essential. 'Through these conclaves held across the country, we aim to increase understanding of HPV and its link to cervical and other cancers,' said Parag Deshmukh, executive director, SII. Experts said vaccinating boys and girls at young age can help strengthen their immune systems before they are exposed to the HPV virus.
Yahoo
4 days ago
- Business
- Yahoo
Global Human Papillomavirus (HPV) Vaccine Market to Hit USD 27.36 Billion by 2032, Fueled by Cancer Prevention Initiatives and Expanding Immunization Coverage
U.S. HPV Vaccine Market to Surpass USD 10.96 Billion by 2032 Amid Strong Government Policies, Widespread Adoption, and Robust Pharmaceutical Innovation Austin, May 30, 2025 (GLOBE NEWSWIRE) -- Human Papillomavirus Vaccine Market Size & Growth Analysis: According to SNS Insider, The global Human Papillomavirus (HPV) vaccine market is projected to grow from USD 8.14 billion in 2024 to USD 27.36 billion by 2032, at a robust CAGR of 16.38% between 2025 and 2032. This growth is propelled by increasing public awareness of HPV-related cancers, the expansion of vaccination programs, and strong government support a Sample Report of Human Papillomavirus (HPV) Vaccine Market@ U.S. Market Outlook In the United States, the HPV vaccine market was valued at USD 3.44 billion in 2024 and is expected to rise to USD 10.96 billion by 2032. Key drivers include advanced healthcare infrastructure, government-backed vaccine mandates, and continued innovation from pharmaceutical leaders like Merck & Co. Market Dynamics Global momentum is building as healthcare authorities emphasize HPV prevention in public health agendas. HPV, the most common viral infection linked to cervical and other anogenital cancers, has become a top target for preventive healthcare. With widespread advocacy from organizations such as the CDC and WHO, vaccination rates are steadily increasing, especially among adolescents. Advancements in vaccine formulations—particularly polyvalent vaccines that offer protection against multiple HPV strains—are also contributing to market expansion. Additionally, collaborative efforts between public health agencies and private vaccine manufacturers have significantly improved vaccine accessibility and distribution. Human Papillomavirus (HPV) Vaccine Market Report Scope Report Attributes Details Market Size in 2024 US$ 8.14 billion Market Size by 2032 US$ 27.36 billion CAGR CAGR of 16.38% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Key Segments By Type (Bivalent, Polyvalent) By Disease Indication (HPV Related Cancer, Genital Warts) By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) Segment Highlights By Type: Polyvalent HPV vaccines led the market in 2024, accounting for over 85% of total revenue. Their broad-spectrum protection, exemplified by Merck's Gardasil 9, has made them the preferred choice among healthcare providers globally. This segment is also the fastest-growing, driven by healthcare professionals' growing preference for comprehensive immunization, improved global supply chains, and expanded funding in low- and middle-income countries. By Disease Indication: Vaccination against HPV-related cancers dominated in 2024, holding about 70% of the market share. This is due to increased recognition of the virus's role in cervical, anal, and oropharyngeal cancers. National and international cancer prevention strategies have embraced HPV vaccination as a key intervention. Meanwhile, the genital warts segment is growing rapidly as public health campaigns raise awareness of non-cancerous HPV effects and promote early vaccination. By Distribution Channel: Hospitals and retail pharmacies represented the largest distribution channels in 2024, capturing around 60% of the market. These outlets offer convenient access and are well-integrated into national immunization programs. Pharmacists and healthcare providers play a crucial role in promoting vaccine uptake. Online pharmacies and e-clinics are emerging as the fastest-growing channels, driven by telehealth growth, digital accessibility, and consumer demand for convenience and home-based services. Need Any Customization Research on Human Papillomavirus (HPV) Vaccine Market, Enquire Now@ Regional Insights North America remained the dominant market in 2024, supported by strong healthcare infrastructure, insurance coverage, and school-based vaccination programs. The presence of major pharmaceutical manufacturers further reinforces regional leadership. The Asia-Pacific region is witnessing the fastest growth, fueled by rising awareness, improved healthcare systems, and government-led initiatives. Countries like India, China, and Japan are increasing immunization budgets and implementing widespread campaigns, including India's national cervical cancer vaccination drive. Major Players Analysis Listed in this Report are: Merck & Co. Inc. GlaxoSmithKline plc (GSK) Serum Institute of India Pvt. Ltd. Sanofi Pasteur SA Pfizer Inc. Inovio Pharmaceuticals Inc. Walvax Biotechnology Co. Ltd. Bharat Biotech International Ltd. Johnson & Johnson Services Inc. Moderna Inc. Gilead Sciences Inc. Recent Developments January 2025: Merck faces a USD 8 billion lawsuit over Gardasil, with an active jury trial addressing alleged side effects and product safety. January 2025: GSK discontinued development of its Phase 2 HPV vaccine candidate, citing a lack of competitive advantage and efficacy potential. October 2024: The Indian government partnered with Serum Institute of India to launch Cervavac in a national immunization drive targeting adolescent girls. Buy a Single-User PDF of Human Papillomavirus (HPV) Vaccine Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Human Papillomavirus (HPV) Vaccine Market by Type 8. Human Papillomavirus (HPV) Vaccine Market by Disease Indication 9. Human Papillomavirus (HPV) Vaccine Market by Distribution Channel 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
24-05-2025
- Health
- Time of India
Docs push for HPV vax for both genders
Kolkata: Doctors in the city stressed the importance of the HPV (Human papillomavirus) vaccine for both the genders, pointing out that the virus did not discriminate between male and female and hence, it was important to adopt this gender-neutral vaccine to prevent HPV-related cancers. Though HPV causes cervical cancer in women, it can affect men with cancers of the anus, penis and oropharynx. India has an indigenously developed quadrivalent HPV vaccine, which covers four types of the virus at a lower cost. Experts, who attended the Conquer HPV & Cancer Conclave in Kolkata on Friday, said as HPV infection peaked between 15 and 25 years, early awareness and timely prevention were needed. Gynaecologists and paediatricians, who advocated for the vaccine to be part of the national immunisation programme, pointed out HPV was transmitted sexually, so the ideal time for vaccination was between 9 and 14 years, before youngsters became sexually active. The expert panel included gynaecological cancer surgeon Dipanwita Banerjee, paediatricians Pallab Chattopadhyay, Abhijit Sarkar, Jaydeep Choudhury and gynaecologists Basab Mukherjee and Dibyendu Banerjee. Get the latest lifestyle updates on Times of India, along with Brother's Day wishes , messages and quotes !
Irish Examiner
21-05-2025
- Health
- Irish Examiner
Concerns raised over lack of clarity on resumption of Laura Brennan HPV catch-up scheme
Serious concerns have been raised that the Government has "abandoned" its commitment to restart the Laura Brennan HPV catch-up programme. Taoiseach Micheál Martin was unable to provide clarity around when such a programme, which would target thousands of young people who miss out on the vaccine each year, will be rolled out. Campaigners have raised concerns around a backslide in uptake of the vaccine which can prevent a number of cancers, including cervical and throat cancer, and are urging the coalition to restart what was previously a highly successful catch-up programme. Raising the issue in the Dáil, Roderic O'Gorman pointed out that the vaccination rates have been dropping since 2019, and around 16,000 young people now do not get it each year. He said the programme for Government pledges to extend the Laura Brennan HPV catch-up vaccination programme to anyone under 25 who missed the original vaccination. "I have been in touch with both the department of health and the HSE to find out when the new programme will run. No one has been able to give me a straight answer," he said. They tell me how important the HPV vaccine is. I agree. They tell me they are going to run a distinct programme for minority groups. That is brilliant. However, no one can tell me when the Laura Brennan programme will run again. "I am worried that they have decided not to do it and more importantly, the Irish Cancer Society is concerned that this scheme is not going to run again," the Green Party leader said. Mr Martin said significant progress has been made in achieving the goal of eradicating HPV-related cancers through the vaccine. "I will check with the minister for health in respect of the catch-up programme. I will ask the minister to revert back to the deputy in respect of it. It is a fair question to raise and I will follow it up." Afterwards, Mr O'Gorman said he was "disappointed" that the Taoiseach could not provide an update on the status of the catch-up programme. During the 2022/23 school year, 80% of girls and around 77% of boys received the HPV jab. However, this is down since the 2019/20 academic year — when 84.1% of girls and 81.5% of boys took up the vaccine. Read More Should we all consider getting vaccinated against HPV?
